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A PROSPECTIVE PILOT STUDY OF THYMOGLOBULIN, CYCLOSPORINE
(CSA) AND MMF AS GVHD PROPHYLAXIS IN UNRELATED DONOR
(URD) HCT USING FLUDARABINE AND MELPHALAN (flu/mel) FOR
HIGH-RISK PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
Rodriguez, R.1, Nademanee, A.1, Fang, Y.1, Dagis, A.1, Sahebi, F.2,
Parker, P.1, Snyder, D.1, Smith, E.1, Nakamura, R.1, Pullarkat, V.1,
Senitzer, D.1, Zain, J.1, Stein, A.1, Patane, K.1, Forman, S.1 1. City of
Hope Comprehensive Cancer Center, Duarte, CA; 2. Southern Califor-
nia Permanente Medical Group, Los Angeles, CA.
Sequential pilot studies at City of Hope using CSA/MMF based
prophylaxis in the URD reduced intensity setting have shown high
rates of acute GVHD (grade 3-4, 40%; lethal 27%, Rodriguez et
al., Bone Marrow Transplant, 2004) that are similar to historical
controls using CSA or tacrolimus MTX. Emerging data suggest
a lower incidence of GVHD with Thymoglobulin. We are there-
fore conducting a prospective study adding Thymoglobulin to
CSA/MMF for URD HCT using ﬂu/mel; preliminary results are
reported. The GVHD prophylaxis consists of CSA 3 mg/kg/d
(beginning day 1), MMF 15 mg/kg 3/d (beginning day 0), and
Thymoglobulin 7.5 mg/kg total dose (day4 to day1/0). Fifteen
patients (pts) have been enrolled, 2 discontinued Thymoglobulin
due to infusional toxicities, and 11 are evaluable for acute GVHD.
The median age is 50 years (33-63), 10 male, 3 female. Diagnoses
include: myeloﬁbrosis (4), B-cell NHL (4), AML (2), Hodgkin (1),
myeloma (1), bone marrow failure (1). Stem cell source was all PB;
median CD34 cell dose of 7.19  106/kg (range 4-19  10 6).
Donor/recipients were HLA allele matched except for 3 pairs with
allele mismatch at class I, and one at both class I and DRB1.
Manageable infusional toxicities with Thymoglobulin were seen in
11 patients. Durable neutrophil engraftment was seen in all pts
with a median time to ANC	500 of 14 days (range 11-22). Day 30
STR analysis in bone marrow MNC was 100% donor in all but 1
pt (94%). With a median follow-up of 6 months (range 1-14
months), 12/13 pts are alive; 1 pt died of diffuse alveolar hemor-
rhage; 1 pt with diffuse large cell NHL has relapsed, others are in
remission. Acute GVHD grade 4, 3 and 2 was seen in 1/11 (9%),
1/11 (9%), and 5/11 (45%) pts, respectively; the only pt with grade
4 GVHD inadvertently received a CD34 cell dose of 19  106/kg.
All pts responded to treatment. Chronic GVHD has not been
observed in any of these pts. EBV reactivation was seen in 3 pts,
and all responded to a single infusion of rituximab. CMV reacti-
vation was seen in 2 pts, including one with CMV pneumonia;
another had CMV colitis without blood reactivation. No other
opportunistic infections have been observed. These preliminary
results suggest that Thymoglobulin as given in this protocol is safe
but infusional toxicities are common. The incidence of severe acute
GVHD appears lower than historical controls; 100-day TRM,
chronic GVHD and relapse rates are presently very low; EBV
reactivation is manageable and CMV disease has been observed.
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ALLOREACTIVE MEMORY T CELLS INDUCE CHRONIC GRAFT-VERSUS-
HOST DISEASE
Zhang, Y.1, Hexner, E.1, Frank, D.2, Joe, G.1, Emerson, S.G.1 1.
Department of Medicine, University of Pennsylvania School of Medicine,
Philadelphia, PA; 2. Department of Pathology, University of Pennsyl-
vania School of Medicine, Philadelphia, PA.
Although it is known that chronic graft-versus-host disease
(GVHD) may involve both cellular and humoral immunity, the
basic pathophysiology of chronic GVHD remains poorly under-
stood, in part due to a lack of experimental models. We have
recently demonstrated that alloreactive memory T cells develop in
hosts with acute GVHD and mediate persistent host tissue injury.
However, whether alloreactive memory T cell-mediated persistent
host tissue injury causes chronic GVHD has not been explored.
Using mouse models of allogeneic bone marrow transplantation
(allo-BMT), we characterized GVHD pathology in secondary
hosts receiving alloreactive memory T cells that developed in
primary recipient mice with acute GVHD after allo-BMT. 2 105
B6 alloreactive CD4 effector/effector memory (E/EM) T cells
isolated from primary GVHD BALB.B mice 35 days after trans-
plantation of donor B6 CD4 and CD8 naive T cells caused clinical
GVHD in secondary BALB.B recipients with signiﬁcantly delayed
onset, while administration of BALB.B mice with either 4 105 B6
CD4 naive T cells or 4  105 CD8 naive T cells failed to induce
GVHD. GVHD occurred in secondary BALB.B recipients by day
35, and peaked between days 50 to 70 after transplantation. Con-
sequently, as many as 60% of these secondary BALB.B recipients
of alloreactive CD4 E/EM T cells succumbed to GVHD from day
50 to day 90 following adoptive transfer. This was in sharp contrast
to the observation that acute GVHD developed in primary
BALB.B mice receiving donor B6 CD4  CD8 naive T cells as
early as day 7 after transplantation. Histologic evaluation showed
that while both B6 naive T cells (CD4CD8) and alloreactive
CD4 E/EM T cells mediated lichenoid-like cutaneous inﬂamma-
tion at later stage in hosts that survived over 50 days after trans-
plantation, donor naive T cells but not alloreactive CD4 E/EM
induced severe acute gastro-intestinal inﬂammation. Like CD4
E/EM T cells, 4  105 alloreactive CD8 E/EM T cells that were
isolated from primary GVHD BALB.B mice receiving B6 CD4
and CD8 naive T cells also caused GVHD in secondary BALB.B
recipients with delayed onset. In these secondary BALB.B recipi-
ents of alloreactive CD8 E/EM T cells, the incidence of severe
cutaneous inﬂammation was signiﬁcantly higher than primary
BALB.B recipients of donor naive T cells. All these results suggest
that alloreactive memory T cells responsible for the persistent host
tissue injury may cause chronic GVHD.
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CONDITIONING INTENSITY AND DENDRITIC CELL (DC) ACTIVATION:
IMPLICATIONS FOR GVHD CONTROL USING DC DEPLETING ANTIBOD-
IES
Turner, B.E., Christensen, M.E., Lange, J., Burns, A.M., Hart, D.N.,
Atkinson, K., Munster, D.J., Rice, A.M. Mater Medical Research In-
stitute, South Brisbane, Queensland, Australia.
Graft versus host disease (GVHD) is a major limitation to the
widespread application of allogeneic haematopoietic stem cell
transplantation (HSCT). Dendritic cells (DC) are central to allo-
geneic transplant interactions. Preparative myeloablative condi-
tioning (MAC) regimens aim to ablate the host immune response
and allow haematopoietic reconstitution. Conditioning also facili-
tates cytokine release and the host DC/donor T cell interactions
that initiate GVHD. Reducing the intensity of conditioning (RIC)
regimens can maintain immune anti-leukaemic activity and reduce
treatment related mortality but the overall incidence of GVHD is
unchanged. We hypothesize that this may be due to the increased
persistence of host DC. Whilst there is information on the effects
of MAC on DC, there is no information on the effects of RIC on
DC. We have established murine models of conditioning (MAC 
cyclophosphamide [CY]  800 cGy and RIC  ﬂudarabine 
CY  200 cGy). DC numbers, activation status and subset com-
position were studied each day of the conditioning regimens. In the
absence of donor cells, a signiﬁcantly higher proportion of plas-
macytoid DC (pDC) was documented in mice receiving MAC as
opposed to RIC (P  .001), but mice that received RIC have
signiﬁcantly higher absolute numbers of host pDC. Subsequent
HSCT experiments indicate similar levels of donor DC chimerism
between the two conditioning regimens. The question remains as
whether the residual host DC are pDC and whether this may
explain the delayed GVHD in RIC transplant recipients. Strategic
administration of DC depleting antibodies could be an effective
means to control GVHD. Intra-peritoneal (ip) injection of N418,
a monoclonal antibody to mouse leukocyte integrin CD11c de-
pleted murine DC in vivo. Preliminary experiments show elimina-
tion of 50% of DC after injection of N418 (500 mg). Subsequent
experiments show that 1 mg of N418 is sufﬁcient to signiﬁcantly
delay, but not prevent, GVHD in a full MHC mismatched model
of HSCT (P  .025). Together, these observations suggest that
increasing antibody concentration and prolonged administration
may be required to prevent GVHD. The successful application of
DC depletion to control GVHD will improve the safety of HSCT
for patients with leukaemia.
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